Chemical formula: C₂₆H₄₀O₅ Molecular mass: 432.593 g/mol PubChem compound: 5311221
The active substance latanoprost, a prostaglandin F2α analogue, is a selective prostanoid FP receptor agonist which reduces the intraocular pressure (IOP) by increasing the outflow of aqueous humour. Reduction of the IOP in man starts about three to four hours after administration and maximum effect is reached after eight to twelve hours.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| S01EE01 | Latanoprost | S Sensory organs → S01 Ophthalmologicals → S01E Antiglaucoma preparations and miotics → S01EE Prostaglandin analogues |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| XALATAN Ophthalmic solution | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| XALATAN Eye drops, solution | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Latanoprost is an active ingredient of these brands:
Austria (AT)
Croatia (HR)Cyprus (CY)
Ecuador (EC)Estonia (EE)Finland (FI)France (FR)Germany (DE)Hong Kong (HK)
Ireland (IE)
Israel (IL)
Italy (IT)Lithuania (LT)Netherlands (NL)New Zealand (NZ)Nigeria (NG)
Poland (PL)
Romania (RO)Singapore (SG)
South Africa (ZA)Spain (ES)Tunisia (TN)Turkey (TR)United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
